Condensed Consolidated Statements of Changes in Stockholders Equity - USD ($) $ in Thousands	Ayala Asset Purchase Agreement Common Stock	Ayala Asset Purchase Agreement Additional Paid-in Capital	Ayala Asset Purchase Agreement	Zentalis Asset Purchase Agreement Common Stock	Zentalis Asset Purchase Agreement Additional Paid-in Capital	Zentalis Asset Purchase Agreement	ATM	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Total
Balance at Dec. 31, 2023								$ 4	$ 342,663	$ 22	$ (222,807)	$ 119,882
Balance (in shares) at Dec. 31, 2023								43,251,778
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense									2,159			2,159
Issuance of common stock		$ 50,645	$ 50,645		$ 23,388	$ 23,388		$ 2	215,408			215,410
Issuance of common stock (in shares)	2,175,489			2,298,586				11,500,000
Exercise of stock options									171			171
Exercise of stock options (in shares)								125,704
Exercise of common stock warrants									3,427			3,427
Exercise of common stock warrants (in shares)								342,686
Unrealized gain on marketable securities										(18)		(18)
Net loss											(129,492)	(129,492)
Balance at Mar. 31, 2024								$ 6	637,861	4	(352,299)	285,572
Balance (in shares) at Mar. 31, 2024								59,694,243
Balance at Dec. 31, 2024								$ 6	696,872	57	(515,770)	181,165
Balance (in shares) at Dec. 31, 2024								64,460,829
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense									5,703			5,703
Issuance of common stock								$ 3	161,742			161,745
Issuance of common stock (in shares)							0	22,258,064
Exercise of stock options									213			$ 213
Exercise of stock options (in shares)								236,962				256,055
Unrealized gain on marketable securities										(60)		$ (60)
Net loss											(41,640)	(41,640)
Balance at Mar. 31, 2025								$ 9	$ 864,530	$ (3)	$ (557,410)	$ 307,126
Balance (in shares) at Mar. 31, 2025								86,955,855